Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy.

Trial Profile

Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms SEL-I-METRY
  • Most Recent Events

    • 01 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 01 Aug 2016 Planned initiation date changed from 1 Jun 2016 to 1 Sep 2016.
    • 01 Aug 2016 Status changed from recruiting to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top